Towards a TDP-43-based biomarker for ALS and FTLD

Towards a TDP-43-based biomarker for ALS and FTLD

TDP-43 accumulates in nerve cells of nearly all cases of amyotrophic lateral sclerosis (ALS, the commonest form of motor neuron disease) and in the majority of Tau-negative frontotemporal lobar degeneration (FTLD). There is currently no biochemical test or marker of disease activity for ALS or FTLD...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Feneberg, E, Gray, E, Ansorge, O, Talbot, K, Turner, M
Format:	Journal article
Wydane:	Springer US 2018

Podobne zapisy

Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP
od: Feneberg, E, i wsp.
Wydane: (2021)

Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
od: Sarah Pickles, i wsp.
Wydane: (2022-07-01)

The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
od: Britt A. Berning, i wsp.
Wydane: (2019-04-01)

FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion.
od: Bäumer, D, i wsp.
Wydane: (2014)

TDP-43 based biomarker development in amyotrophic lateral sclerosis
od: Feneberg, E
Wydane: (2019)

NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility
od: Amanda M. Gleixner, i wsp.
Wydane: (2022-06-01)

Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
od: Luigi Fiondella, i wsp.
Wydane: (2023-04-01)

Codon-optimized TDP-43 mediates neurodegeneration in a Drosophila model of ALS/FTLD
od: Tanzeen Yusuff, i wsp.
Wydane: (2023-03-01)

Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology
od: Feneberg, E, i wsp.
Wydane: (2020)

C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation
od: Keith A. Josephs, i wsp.
Wydane: (2019-07-01)

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.
od: Barbara Scherz, i wsp.
Wydane: (2018-01-01)

TDP-43 Proteinopathy Specific Biomarker Development
od: Isabell Cordts, i wsp.
Wydane: (2023-02-01)

Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
od: Shunsuke Koga, i wsp.
Wydane: (2023-07-01)

Publisher Correction to: Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
od: Shunsuke Koga, i wsp.
Wydane: (2023-07-01)

TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy
od: Turner, B, i wsp.
Wydane: (2008)

An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress
od: Feneberg, E, i wsp.
Wydane: (2020)

Regional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology
od: V. Borghesani, i wsp.
Wydane: (2020-01-01)

An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress
od: Emily Feneberg, i wsp.
Wydane: (2020-10-01)

Aberrant TDP‐43 phosphorylation: a key wind gap from TDP‐43 to TDP‐43 proteinopathy
od: Zi‐Qi Huang, i wsp.
Wydane: (2021-06-01)

TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy
od: Lumi Zhang, i wsp.
Wydane: (2020-01-01)

ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation.
od: Adam K Walker, i wsp.
Wydane: (2013-01-01)

The role of mitochondrial dysfunction and ER stress in TDP-43 and C9ORF72 ALS
od: Dafinca, R, i wsp.
Wydane: (2021)

Advancements in TDP-43 research: Towards biomarkers and therapeutic targets for amyotrophic lateral sclerosis
od: Yuhan Wu, i wsp.
Wydane: (2025-03-01)

TDP-43 as a potential retinal biomarker for neurodegenerative diseases
od: Margit Glashutter, i wsp.
Wydane: (2025-02-01)

Low T-cell reactivity to TDP-43 peptides in ALS
od: Swetha Ramachandran, i wsp.
Wydane: (2023-07-01)

CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
od: Vivian I. Ko, i wsp.
Wydane: (2024-06-01)

Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models.
od: Nirma D Perera, i wsp.
Wydane: (2014-01-01)

Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models.
od: Nirma D Perera, i wsp.
Wydane: (2014-01-01)

In vitro prion-like behaviour of TDP-43 in ALS
od: Phillip Smethurst, i wsp.
Wydane: (2016-12-01)

Restoring functional TDP-43 oligomers in ALS and laminopathic cellular models through baicalein-induced reconfiguration of TDP-43 aggregates
od: Hsiang-Yu Chang, i wsp.
Wydane: (2024-02-01)

TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy
od: Rachel Atkinson, i wsp.
Wydane: (2021-02-01)

LIPIDS ALTERATION IN TDP-43
od: Irene García Toledo, i wsp.
Wydane: (2023-10-01)

The cooperative binding of TDP-43 to GU-rich RNA repeats antagonizes TDP-43 aggregation
od: Juan Carlos Rengifo-Gonzalez, i wsp.
Wydane: (2021-09-01)

TDP-43: From Alzheimer’s Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy
od: Wendi Huang, i wsp.
Wydane: (2020-02-01)

The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43.
od: Ya-Fei Xu, i wsp.
Wydane: (2013-01-01)

Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology
od: Kyota Fujita, i wsp.
Wydane: (2018-01-01)

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use
od: Juan I. López-Carbonero, i wsp.
Wydane: (2024-06-01)

Disease-modifying effects of metabolic perturbations in ALS/FTLD
od: Ali Jawaid, i wsp.
Wydane: (2018-12-01)

Importance of Functional Loss of FUS in FTLD/ALS
od: Shinsuke Ishigaki, i wsp.
Wydane: (2018-05-01)

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy
od: Julie C Necarsulmer, i wsp.
Wydane: (2023-10-01)